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Summary
Clinical next‑generation sequencing (NGS) has evolved from a
novel and promising test modality into a necessary and integral
part of diagnosis and prediction of response to therapy. The
technology to implement NGS, while complex, is now within
the reach of most clinical laboratories. As NGS technology
has advanced, a variety of professional and regulatory bodies
have developed guidance for clinical laboratories seeking to
develop NGS assays [Figure 1].[5,6]
The article by Roy et al. in the January issue of JMD is the
most recent publication in a series of recommendations for
clinical NGS[1] led by the Association for Molecular Pathology.
In earlier JMD papers, Li et al.[2] and Richards et al.[3]
established the standards for reporting of somatic and germline
sequence variants, respectively. Their work focused on the best
practices for selection and use of reference databases and on
the evidence‑based, clinically focused variant classification.
Li et al. based their recommendations, in part, on surveys of
variant classification from Association for Molecular Pathology
(AMP) member laboratories. These surveys highlighted the
broad differences not only in how variants were classified but
also in the underlying bioinformatics pipelines each laboratory
used to identify variants.
Targeted oncology sequencing panels are among the most
popular applications of NGS. Jennings et al. outlined the
recommendations of a second AMP working group for
validation of these NGS‑based oncology panels.[4] This paper
covered panel design, wet laboratory method, and universal
validation issues such as reproducibility, limit of detection,
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and number and the type of samples needed. The authors also
noted the diversity of available bioinformatics tools and the
importance of different computational approaches based on
variant class and assay design. However, detailed guidance for
validation of bioinformatics tools was left to a later working
group.
The most recent publication by Roy et al. provides the much
needed guidance on the design and use of bioinformatics
pipelines in clinical NGS. The recommendations in this article
are informed by a systematic review of 147 publications on
validation of clinical NGS bioinformatics. This literature
review again highlighted the dissimilarity of computational
methods used to align sequence reads and identify variants.
Each of the recent AMP recommendation papers is the result
of collaboration with other organizations having expertise
in particular aspects of clinical NGS validation. With its
focus on bioinformatics, the most recent recommendations
were formed in partnership with the College of American
Pathologists (CAP) and the American Medical Informatics
Association.

Comments
The recommendations in Roy et al. are extensive and address
the issues of validation, study design, selection of appropriate
and representative variants, information security, data integrity,
quality control/quality assurance, and regulatory compliance.
Throughout, the focus of these recommendations remains on
the specimen and its associated clinicopathological setting.
Outside of de facto file format standards, there is no effort to

Figure 1: Summary of guidelines and recommendations for clinical next-generation sequencing
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recommend any specific technology. Unlike most clinical testing
approaches, validating all potential findings (variants) on an
NGS panel is impractical, and instead, the authors recommend
that each potential type of variant (single‑nucleotide variant,
indel, etc.) is validated, along with its respective specialized
variant caller. Because the number of potential variants is too
great to validate individually in an analyte‑based approach, the
choice of an appropriate number of representative variants for
use in a method‑based validation approach is of considerable
importance to laboratory directors. To address this issue,
the authors propose a simple but useful formula based on
probability and confidence of variant detection.
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